KSQ Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$156M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • KSQ Therapeutics's estimated annual revenue is currently $22.1M per year.(i)
  • KSQ Therapeutics received $80.0M in venture funding in October 2018.
  • KSQ Therapeutics's estimated revenue per employee is $201,000
  • KSQ Therapeutics's total funding is $156M.

Employee Data

  • KSQ Therapeutics has 110 Employees.(i)
  • KSQ Therapeutics grew their employee count by 59% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M344-2%$634MN/A
#2
$49.6M247-6%N/AN/A
#3
$10.7M53130%N/AN/A
#4
$20.1M10023%$113MN/A
#5
$4M48118%N/AN/A
#6
$1.8M4063%$538MN/A
#7
$40.2M200-11%N/AN/A
#8
$11.6M192-14%$506.4MN/A
#9
$3.7M4588%N/AN/A
#10
$4360M45081175%N/AN/A

KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ksqtx.com.

keywords:N/A

$156M

Total Funding

110

Number of Employees

$22.1M

Revenue (est)

59%

Employee Growth %

N/A

Valuation

N/A

Accelerator

KSQ Therapeutics News

2022-04-17 - Investigators Present 12 Novel Agents During 3 AACR Special ...

... both as a single agent and in combination with PARP inhibitors,” Andrew Wylie, PhD, from KSQ Therapeutics, said in a statement.

2022-03-22 - KSQ Therapeutics to Present Data at the American Association for ...

KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer and autoimmune disease across multiple...

2019-09-13 - TIDAL Unplugged, Emerging Artist Program, Announces ...

... (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics (RUBY); Syros Pharmaceuticals (SYRS); Sana Biotechnology; KSQ Therapeutics; ...

2019-04-16 - KSQ Therapeutics Announces Appointment of Beni B. Wolf ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ Therapeutics today announced the appointment of Beni B. Wolf, MD, PhD, as Chief Medical ...

2019-04-16 - KSQ Therapeutics Announces Appointment of Douglas Pagán ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- KSQ Therapeutics today announced the appointment of Douglas Pagán as Chief Financial Officer.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.3M110-14%$81.1M
#2
$15M110-53%N/A
#3
$17.2M11163%$302M
#4
$18.8M1116%$198.5M
#5
$17.2M11113%N/A

KSQ Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-10-03$76.0MUndisclosedMultipleArticle
2018-10-01$80.0MCMultipleArticle